4563 On Other Exchanges
4563 is not on other exchanges.

anges mg inc (4563) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ANGES MG INC (4563)

Related News

No related news articles were found.

anges mg inc (4563) Related Businessweek News

No Related Businessweek News Found

anges mg inc (4563) Details

AnGes, Inc., a biopharmaceutical company, engages in the research and development of gene-based medical products. It offers Naglazyme, a drug for the treatment of mucopolysaccharidosis VI, an intractable disease. It is also developing hepatocyte growth factor plasmid, a gene therapy in the last stage of clinical development for the treatment of critical limb ischemia, which is a serious impairment of blood circulation in the legs. In addition, the company is developing NFkB Decoy Oligonucleotide, a nucleic-acid medicine for the treatment of immune and inflammatory diseases, such as atopic dermatitis, PTA balloon catheter, and disc degeneration; and cervical intraepithelial neoplasia (CIN) and DNA therapeutic vaccines, as well as Allovectin, a cancer treatment drug. It has alliances with BioLeaders Corporation to develop, manufacture, use, and market CIN vaccine in China; BioMarin Pharmaceutical Inc. to market a drug for the treatment of mucopolysaccharidosis VI; Hosokawa Micron Corporation for the technology development of poly lactic-co-glycolic acid particle preparations containing NF-kB decoy oligonucleotide; Medikit Co., Ltd. to develop, manufacture, and market percutaneous transluminal angioplasty medical device; Mitsubishi Tanabe Pharma Corporation for the treatment of peripheral arterial disease in the United States and japan; SHIONOGI & CO., LTD. for the marketing of drugs for external use containing NF-kB decoy oligonucleotide for the indication of skin diseases; and Vical, Inc. for the development and marketing of Allovectin. The company was formerly known as AnGes MG, Inc. and changed its name to AnGes, Inc. in July 2017. AnGes, Inc. was founded in 1999 and is headquartered in Ibaraki, Japan.

Founded in 1999

anges mg inc (4563) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

anges mg inc
AnGes, Inc. Announces Unaudited Consolidated and Non-Consolidated Earnings Results for the Year Ended December 31, 2017; Provides Earnings Guidance for Year Ending December 31, 2018

AnGes, Inc. announced unaudited consolidated and non-consolidated earnings results for the year ended December 31, 2017. For the year, on consolidated basis, the company reported revenue of JPY 365 million against JPY 514 million a year ago. Operating loss was JPY 3,288 million against JPY 4,763 million a year ago. Ordinary loss was JPY 3,307 million against JPY 4,847 million a year ago. Net loss was JPY 3,764 million or JPY 49.38 per share against JPY 4,776 million or JPY 75.29 per share a year ago. Negative return on Equity was 104.1% compared with 119% for the same period last year. Negative return on asset was 77.8% compared with 104.3% for the same period last year. Cash flows used in operating activities was JPY 2,991 million compared with JPY 4,983 million for the same period last year. Loss before income taxes was JPY 3,744.187 million compared to JPY 4,760.670 million a year ago. Purchase of property, plant and equipment was JPY 7.032 million compared to JPY 49.545 million a year ago. Purchase of intangible assets was JPY 2.240 million compared to JPY 21.450 million a year ago. For the year, on non-consolidated basis, the company reported revenue of JPY 365 million against JPY 514 million a year ago. Operating loss was JPY 3,328 million against JPY 4,796 million a year ago. Ordinary loss was JPY 3,349 million against JPY 4,762 million a year ago. Net loss was JPY 3,777 million or JPY 49.55 per share against JPY 4,683 million or JPY 73.82 per share a year ago. For the year ending December 31, 2018, the company expects net sales is to be JPY 365 million, operating loss is to be JPY 2,500 million, ordinary loss is to be JPY 2,500 million and net loss is to be JPY 2,500 million or JPY 31.36 per share.

AnGes, Inc. Submits Application for Marketing Approval to PMDA for HGF Gene Therapy for Critical Limb Ischemia

AnGes, Inc. announced the submission of an application for marketing approval to the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan for HGF plasmid, an investigational gene therapy for the treatment of critical limb ischemia (CLI), the most severe condition of peripheral arterial disease. The submission is based on the positive results from the randomized, placebo-controlled phase 3 trial and investigator-led clinical study conducted in Japan. AnGes anticipates being granted conditional approval under the regulatory scheme of “Approval with Conditions and Time Limit” for regenerative medicines. The review process is expected to take approximately one year. HGF plasmid has the potential to be one of the first gene therapy products to be approved for a non-genetic disease with chronic conditions. AnGes grants to Mitsubishi Tanabe Pharma Corporation the marketing rights to HGF plasmid for peripheral arterial diseases including CLI in Japan and the US. Once approved, Mitsubishi Tanabe will be responsible for the sales and marketing of the product.

AnGes, Inc. to Report Fiscal Year 2017 Results on Feb 02, 2018

AnGes, Inc. announced that they will report fiscal year 2017 results on Feb 02, 2018


The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

4563 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4563.
View Industry Companies

Industry Analysis


Industry Average

Valuation 4563 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 120.3x
Price/Book 12.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 119.8x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact ANGES MG INC, please visit www.anges-mg.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.